EX-10.12 3 omga-ex10_12.htm EX-10.12 EX-10.12

img245684044_0.jpg 

 

Exhibit 10.12

 

 

October 5, 2022

 

 

Richard A. Young, Ph.D.

1 Longfellow Place, Apt. 3510

Boston, MA 02114

 

Re: Amendment #3 to Consulting Agreement

 

Dear Richard:

 

This is in reference to the Consulting Agreement between VL42, d/b/a Omega Therapeutics, Inc., and Richard A. Young, Ph.D. dated November 7, 2016 (the “Agreement”). All capitalized terms used in this letter and not otherwise defined in this letter shall have the same meaning as in the Agreement.

Whereas the parties to the Agreement have agreed to extend the term of the Agreement through November 7, 2023, the parties hereby amend and restate Section 2 of the Agreement in its entirety, to read as follows:

 

2. Term. This Agreement shall commence on the Effective Date hereof and shall continue until November 7, 2023 unless sooner terminated in accordance with the provisions of Section 4 herein or unless further extended by mutual written consent of the parties (such period being referred to as the “Consultation Period”).

 

Please sign below to confirm you agree with this Amendment, and kindly return a copy of the signed letter to us.

Sincerely,

 

/s/ Thomas McCauley

 

Thomas McCauley

 

Chief Scientific Officer

 

 

 

Agreed:

 

 

 

/s/ Richard A. Young

 

Name: Richard A. Young, Ph.D.

 

 

 

 

Omega Therapeutics, Inc., 20 Acorn Park Drive, Cambridge, MA 02140 Phone: + 617 949 4539 · www.omegatherapeutics.com